Hillsdale Investment Management Inc. Purchases Shares of 13,300 DexCom, Inc. $DXCM

Hillsdale Investment Management Inc. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,300 shares of the medical device company’s stock, valued at approximately $883,000.

A number of other hedge funds also recently bought and sold shares of DXCM. Holocene Advisors LP bought a new stake in DexCom during the third quarter valued at about $163,964,000. CIBC Private Wealth Group LLC boosted its holdings in DexCom by 374.3% during the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after acquiring an additional 2,294,709 shares during the period. Vanguard Group Inc. raised its position in shares of DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares during the last quarter. Intermede Investment Partners Ltd acquired a new position in shares of DexCom during the fourth quarter valued at about $60,351,000. Finally, Iron Triangle Partners LP acquired a new position in shares of DexCom during the third quarter valued at about $57,196,000. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of a number of research analyst reports. Barclays reaffirmed an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Citigroup reaffirmed a “buy” rating and set a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday. Bank of America cut their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Benchmark initiated coverage on shares of DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $82.42.

DexCom Stock Performance

NASDAQ:DXCM opened at $74.87 on Tuesday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $28.89 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 1.22 and a beta of 1.45. The firm has a 50-day moving average price of $64.32 and a 200 day moving average price of $66.64.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the business posted $0.32 earnings per share. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,871 shares of company stock valued at $2,306,638 over the last quarter. Corporate insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.